bluebird bio Inc logo

bluebird bio Inc Investor Relations Material

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company's product portfolio comprises two clinical-stage lentiviral-based gene therapy product candidates for the treatment of transfusion-dependent b-thalassemia (TDT) and severe sickle cell disease (SCD); and a preclinical-stage gene therapy product candidate for the treatment of childhood cerebral adrenoleukodystrophy. Its clinical development programs include LentiGlobin BB305 program to treat TDT and SCD; and Lenti-D that is in Phase II/III trial to treat cerebral adrenoleukodystrophy. The company has collaboration agreements with Celgene Corporation; Intellia Therapeutics, Inc.; Catalent Biologics LLC; Kite Pharma, Inc.; Genethon S.A.; and University of Pennsylvania. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusett

Latest company events

More about bluebird bio Inc

s

Ticker symbol

BLUE

Country

United States of America

Investor Relations Page

https://investor.bluebirdbio.com/

Dig deeper into the bluebird bio Inc fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot